Cargando…

Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy

Antiaris is a monoherbal decoction produced by the Centre for Plant Medicine Research (CPMR), Mampong-Akuapem, Ghana. It is prepared from the stem bark of Antiaris africana Engl. (Moraceae), prescribed, and dispensed to patients for the management of nervous disorders. This current formulation prese...

Descripción completa

Detalles Bibliográficos
Autores principales: Archer, Mary-Ann, Kumadoh, Doris, Gaizer, Samuel Nii-Bortier, Mensah, Adelaide, Jato, Jonathan, Kyene, Micheal Odoi, Mintah, Susana Oteng, Yeboah, Genevieve Naana, Sodzi, Paul kwesi, Adi-Dako, Ofosua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068321/
https://www.ncbi.nlm.nih.gov/pubmed/35528114
http://dx.doi.org/10.1155/2022/5340953
_version_ 1784700200937324544
author Archer, Mary-Ann
Kumadoh, Doris
Gaizer, Samuel Nii-Bortier
Mensah, Adelaide
Jato, Jonathan
Kyene, Micheal Odoi
Mintah, Susana Oteng
Yeboah, Genevieve Naana
Sodzi, Paul kwesi
Adi-Dako, Ofosua
author_facet Archer, Mary-Ann
Kumadoh, Doris
Gaizer, Samuel Nii-Bortier
Mensah, Adelaide
Jato, Jonathan
Kyene, Micheal Odoi
Mintah, Susana Oteng
Yeboah, Genevieve Naana
Sodzi, Paul kwesi
Adi-Dako, Ofosua
author_sort Archer, Mary-Ann
collection PubMed
description Antiaris is a monoherbal decoction produced by the Centre for Plant Medicine Research (CPMR), Mampong-Akuapem, Ghana. It is prepared from the stem bark of Antiaris africana Engl. (Moraceae), prescribed, and dispensed to patients for the management of nervous disorders. This current formulation presents notable challenges in patients' adherence to treatment regimen due to its bulkiness and bitterness. These challenges have resulted in a decrease in therapeutic outcome. This study sought to transform Antiaris into oral capsules to mask its bitter taste and reduce bulkiness of the product to improve patients' convenience. In this study, four (4) conventional release capsule formulations were successfully prepared from the decoction via wet granulation using corn starch, lactose, light magnesium carbonate (LMC), and microcrystalline cellulose (MCC) and labelled A01, A02, A03, and A04 respectively. The drug-excipient compatibility studies on A01, A02, A03, and A04 were investigated using Fourier transform infrared (FTIR) spectroscopy. The flow properties of the granules as well as the quality assessment of the formulations such as dissolution, disintegration, uniformity of weight, and assay tests were evaluated using pharmacopoeial and nonpharmacopoeial methods. Appropriate models were used to investigate the difference factor (f(1)) and similarity factor (f(2)) of the dissolution profiles of the formulations and Antiaris. From the study, all formulated granules had excellent flow properties with Carr's index from 7.83 to 9.56%, Hausner's ratio from 1.09 to 1.10, and angle of repose from 25.13 to 27.87°. Drug-excipient compatibility studies demonstrated no interaction between extract and used excipients. All formulations passed the uniformity of weight, disintegration, assay, and dissolution tests. Formulation A02 had the highest dissolution efficiency of 100.12%, while A03 recorded the least value of 97.22% in the 1 h dissolution studies. A comparison of their various dissolution profiles, respectively, to that of its decoction demonstrated their similarity, since, in all comparisons, f(2) < 15 and f(1) > 50. This implies that, any of these four formulations could be a good substitute for Antiaris.
format Online
Article
Text
id pubmed-9068321
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-90683212022-05-05 Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy Archer, Mary-Ann Kumadoh, Doris Gaizer, Samuel Nii-Bortier Mensah, Adelaide Jato, Jonathan Kyene, Micheal Odoi Mintah, Susana Oteng Yeboah, Genevieve Naana Sodzi, Paul kwesi Adi-Dako, Ofosua Adv Pharmacol Pharm Sci Research Article Antiaris is a monoherbal decoction produced by the Centre for Plant Medicine Research (CPMR), Mampong-Akuapem, Ghana. It is prepared from the stem bark of Antiaris africana Engl. (Moraceae), prescribed, and dispensed to patients for the management of nervous disorders. This current formulation presents notable challenges in patients' adherence to treatment regimen due to its bulkiness and bitterness. These challenges have resulted in a decrease in therapeutic outcome. This study sought to transform Antiaris into oral capsules to mask its bitter taste and reduce bulkiness of the product to improve patients' convenience. In this study, four (4) conventional release capsule formulations were successfully prepared from the decoction via wet granulation using corn starch, lactose, light magnesium carbonate (LMC), and microcrystalline cellulose (MCC) and labelled A01, A02, A03, and A04 respectively. The drug-excipient compatibility studies on A01, A02, A03, and A04 were investigated using Fourier transform infrared (FTIR) spectroscopy. The flow properties of the granules as well as the quality assessment of the formulations such as dissolution, disintegration, uniformity of weight, and assay tests were evaluated using pharmacopoeial and nonpharmacopoeial methods. Appropriate models were used to investigate the difference factor (f(1)) and similarity factor (f(2)) of the dissolution profiles of the formulations and Antiaris. From the study, all formulated granules had excellent flow properties with Carr's index from 7.83 to 9.56%, Hausner's ratio from 1.09 to 1.10, and angle of repose from 25.13 to 27.87°. Drug-excipient compatibility studies demonstrated no interaction between extract and used excipients. All formulations passed the uniformity of weight, disintegration, assay, and dissolution tests. Formulation A02 had the highest dissolution efficiency of 100.12%, while A03 recorded the least value of 97.22% in the 1 h dissolution studies. A comparison of their various dissolution profiles, respectively, to that of its decoction demonstrated their similarity, since, in all comparisons, f(2) < 15 and f(1) > 50. This implies that, any of these four formulations could be a good substitute for Antiaris. Hindawi 2022-04-27 /pmc/articles/PMC9068321/ /pubmed/35528114 http://dx.doi.org/10.1155/2022/5340953 Text en Copyright © 2022 Mary-Ann Archer et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Archer, Mary-Ann
Kumadoh, Doris
Gaizer, Samuel Nii-Bortier
Mensah, Adelaide
Jato, Jonathan
Kyene, Micheal Odoi
Mintah, Susana Oteng
Yeboah, Genevieve Naana
Sodzi, Paul kwesi
Adi-Dako, Ofosua
Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy
title Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy
title_full Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy
title_fullStr Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy
title_full_unstemmed Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy
title_short Development and In Vitro Evaluation of Oral Capsules from Antiaris: A Convenient Substitute for Peripheral Neuropathy
title_sort development and in vitro evaluation of oral capsules from antiaris: a convenient substitute for peripheral neuropathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068321/
https://www.ncbi.nlm.nih.gov/pubmed/35528114
http://dx.doi.org/10.1155/2022/5340953
work_keys_str_mv AT archermaryann developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy
AT kumadohdoris developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy
AT gaizersamuelniibortier developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy
AT mensahadelaide developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy
AT jatojonathan developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy
AT kyenemichealodoi developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy
AT mintahsusanaoteng developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy
AT yeboahgenevievenaana developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy
AT sodzipaulkwesi developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy
AT adidakoofosua developmentandinvitroevaluationoforalcapsulesfromantiarisaconvenientsubstituteforperipheralneuropathy